Charles River Laboratories Intl. Inc vs Cloudflare Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $300.93 (market cap $14.23B), while Cloudflare Inc trades at $350 (market cap $121.74B). The key difference: Cloudflare Inc is far larger — about 8.6× Charles River Laboratories Intl. Inc's market cap, and Cloudflare Inc is more actively traded (2,433,002 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Cloudflare Inc for 61 Days on average.
| CRL | NET | |
|---|---|---|
Market Cap | $14.23B | $121.74B |
Volume | 1,176,885 | 2,433,002 |
Sector | Health | Technology |
52-Week High | $310.77 | $359.60 |
52-Week Low | $149.93 | $160.16 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $17.06B | $121.11B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with $2.17 billion in 2025 sales, though profitability remains challenged with a -8.21% net margin. Recent technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains overwhelmingly positive with 71% buy ratings. The company's recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation in the connectivity cloud space.
Cloudflare presents a growth story with expanding enterprise adoption but faces valuation concerns at current levels. The stock's premium multiples (P/S 47.88) require continued execution against strong revenue growth targets. Key risks include persistent profitability challenges and competitive pressures in the cloud security market, while catalysts include AI-driven security demand and platform consolidation opportunities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →